痰热清联合更昔洛韦治疗小儿呼吸道合胞病毒性肺炎的疗效和安全性.docVIP

痰热清联合更昔洛韦治疗小儿呼吸道合胞病毒性肺炎的疗效和安全性 　　[摘要] 目的 临床运用痰热清联合更昔洛韦治疗小二呼吸道合胞病毒性肺炎，并对其疗效与安全性进行评价。方法 回顾分析2013年1月―2014年3月该院儿科门诊收治的80例呼吸道合胞病毒性肺炎患儿临床资料，随机将其分成两组进行比较，每组各位40例。2组患儿均统一接受一般常规治疗，对照组另使用利巴韦林治疗，观察组在对照基础上使用痰热清联合更昔洛韦治疗，观察两组临床治疗效果以及治疗过程中所出现的不良反应，同时对2组结果进行对比。 结果 观察组总体治疗有效率为92.5%，对照组总体治疗有效率为82.5%，可明显看出观察组治疗效果更佳，差异有统计学意义（P0.05）。结论 临床使用痰热清联合更昔洛韦治疗小儿呼吸道合胞病毒性肺炎取得良好治疗效果，并且安全性较高，适合儿童临床用药的推广。 　　[关键词] 合胞病毒性肺炎；更昔洛韦；痰热清 　　[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-0742（2015）05（c）-0108-02 　　[Abstract] Objective To evaluate the clinical effect and safety of tanreqing combined with ganciclovir in curing respiratory syncytial virus pneumonia of children. Methods A retrospective analysis of the clinical data of 80 children from 2013 January to 2014 March with respiratory syncytial virus pneumonia in our hospital was made. The children were randomly divided into two groups， with 40 patients in each group. Both groups were treated with conventional therapy. The control group was treated with ribavirin， and the observation group was treated with tanreqing + ganciclovir in addition to ribavirin. The clinical curative effects and adverse reactions of the two groups were observed and compared in the treatment process. Results The total treatment effective rate of the observation group was 92.5%， and the total effective rate of the control group was 82.5%. The treatment effect of the observation group was better， which was of statistical difference （P0.05）. Conclusion Tanreqing combined with ganciclovir has good clinical effect and high safety in curing respiratory syncytial virus pneumonia of children， so it is worth promotion in childrens clinical medication. 　　[Key words] Syncytial viral pneumonia； Ganciclovir； Tanreqing 　　小儿肺炎是儿科较常见疾病，对儿童的生命健康具有严重威胁，具有较高的发病率及死亡率，以为WHO列入世界三大儿科疾病之一[1]。病毒性肺炎是小儿肺炎中最为常见类型，具有爆发性流行趋势，危害较大，临床应予以重视。呼吸道合胞病毒性肺炎多发于婴幼儿，存在4～5 d的潜伏期，初期临床症状常表现为鼻塞、咳嗽及高热，随着病情的发展，患儿逐渐表现出呼吸困难、口唇青紫、三凹征及鼻扇等，若不能及时救治，严重将会引起心力衰竭或呼吸功能衰竭[2]。该研究讨论主要围绕痰热清联合更昔洛韦治疗效果及安全性展开，并为临床合理用药提供有力依据。资料整理进行如下汇报。 　　1 资料与